News
Sarepta Therapeutics Stock: FDA Action Triggers 90% Collapse
Sarepta Therapeutics shares have plummeted to just around $14, representing a catastrophic decline of over 90% in the past year. The devastating selloff follows the FDA's request for a voluntary
Merck Aktie: EU-Durchbruch bei seltener Krankheit
Der Darmstädter Pharmakonzern hat einen wichtigen regulatorischen Erfolg erzielt. Die Europäische Arzneimittel-Agentur (EMA) erteilte…
Der Beitrag Merck Aktie: EU-Durchbruch bei seltener Krankheit
EQS-News: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose; profitablerer Umsatzmix erwartet
EQS-Adhoc: Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
Valneva Aktie: Impfstoff-Durchbruch beschert Rückenwind
Die europäische Zulassungsbehörde EMA hat Valneva einen entscheidenden Erfolg beschert: Die Aufhebung der Nutzungsbeschränkung…
Der Beitrag Valneva Aktie: Impfstoff-Durchbruch beschert Rückenwind
Sarepta Therapeutics Stock: Crisis Deepens After Third Death
Sarepta Therapeutics continues its downward spiral after a third patient death was reported in clinical trials, sending the stock plummeting to $18.21 - representing an 84.7% decline over the past
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock
EQS-News: Gerresheimer beendet Gespräche mit Private Equity Investoren über ein potenzielles Übernahmeangebot
EQS-Adhoc: Gerresheimer AG: Gespräche über ein potenzielles Übernahmeangebot beendet
EQS-News: Eckert & Ziegler: Ausbildungsqualität erneut ausgezeichnet
EQS-News: Eckert & Ziegler: Ausbildungsqualität erneut ausgezeichnet
Talente bringen Xiamen voran: Start des „Talent Service Month“ 2025
XIAMEN, China, July 14, 2025 (GLOBE NEWSWIRE) -- Der „Talent Service Month“ 2025 in Xiamen wurde am 10. Juli eröffnet und lud Talente aus aller Welt ein, sich an der Gestaltung einer glänzenden
Astrazeneca Stock: Breakthrough Drug Study Boosts Shares
The British pharmaceutical giant saw its shares surge on Monday, reaching the highest level since mid-June following positive Phase III trial results for its experimental drug Baxdrostat. The
Astrazeneca Stock: Breakthrough Drug Study Boosts Shares
The British pharmaceutical giant saw its shares surge on Monday, reaching the highest level since mid-June following positive Phase III trial results for its experimental drug Baxdrostat. The
Why Wall Street Is Betting on These 3 Comeback Stocks
The first half of 2025 was a tumultuous time for U.S. securities, to put it mildly. The transition to the second Trump administration brought rapidly shifting domestic and international policies
Why Wall Street Is Betting on These 3 Comeback Stocks
The first half of 2025 was a tumultuous time for U.S. securities, to put it mildly. The transition to the second Trump administration brought rapidly shifting domestic and international policies
EQS-News: Gerresheimer im 1. HJ 2025: Umsatz- und Ergebnissprung durch Bormioli Pharma, weiterhin Markteinflüsse im operativen Geschäft
MSD Stock: Pharma Giant's $10 Billion Verona Acquisition
Merck & Co. is poised to make its largest acquisition in two years, agreeing to purchase British biotech firm Verona Pharma for approximately $10 billion. The pharmaceutical giant will pay $107 per
MSD Stock: Pharma Giant's $10 Billion Verona Acquisition
Merck & Co. is poised to make its largest acquisition in two years, agreeing to purchase British biotech firm Verona Pharma for approximately $10 billion. The pharmaceutical giant will pay $107 per
Rhythm Stock: Obesity Drug Spurs Analyst Optimism
Rhythm Pharmaceuticals has captured Wall Street's attention following impressive Phase 2 results for its experimental obesity medication, Bivamelagon. The biotech company's shares surged 10% after
Do They Know Something? Insiders & Congress Buy UnitedHealth
UnitedHealth Group (NYSE: UNH) has spent a significant amount of time in the sick bay for the first half of 2025, but it’s showing signs of recovery.
Let’s get the bad news out of the way
Do They Know Something? Insiders & Congress Buy UnitedHealth
UnitedHealth Group (NYSE: UNH) has spent a significant amount of time in the sick bay for the first half of 2025, but it’s showing signs of recovery.
Let’s get the bad news out of the way
Johnson & Johnson reicht bei der Europäischen Arzneimittel-Agentur einen Antrag auf Indikationserweiterung für AKEEGA® (niraparib und abirateronacetat-Doppeltablette) zur Behandlung von erwachsenen Patienten mit metastasiertem hormonsensitivem Prosta
Der Antrag basiert auf den Ergebnissen der Phase III-Studie AMPLITUDE, in der niraparib in Kombination mit abirateronacetat plus prednison oder prednisolon im Vergleich zur aktuellen
Why Centene Stock Dropped 40% — And Whether It's a Buy Now
For healthcare stock Centene (NYSE: CNC), July 2 was indisputably disastrous. Shares closed down by over 40% that day, resulting in the firm losing over $11 billion in market capitalization